What is Zacks Research’s Forecast for VRTX Q2 Earnings?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Research analysts at Zacks Research raised their Q2 2025 earnings per share (EPS) estimates for shares of Vertex Pharmaceuticals in a report released on Tuesday, February 4th. Zacks Research analyst R. Department now forecasts that the pharmaceutical company will post earnings per share of $3.77 for the quarter, up from their prior estimate of $3.76. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is ($1.93) per share. Zacks Research also issued estimates for Vertex Pharmaceuticals’ FY2025 earnings at $14.98 EPS, Q1 2026 earnings at $3.77 EPS and Q2 2026 earnings at $3.99 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The business had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. During the same period in the prior year, the firm earned $3.67 EPS. The business’s revenue for the quarter was up 11.6% on a year-over-year basis.

Several other equities analysts also recently issued reports on the stock. Raymond James reaffirmed a “market perform” rating on shares of Vertex Pharmaceuticals in a report on Thursday, October 10th. StockNews.com downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 21st. HC Wainwright increased their target price on shares of Vertex Pharmaceuticals from $535.00 to $550.00 and gave the company a “buy” rating in a research report on Friday, January 31st. Stifel Nicolaus increased their target price on shares of Vertex Pharmaceuticals from $490.00 to $494.00 and gave the company a “hold” rating in a research report on Monday, December 16th. Finally, Wells Fargo & Company cut shares of Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 target price for the company. in a research report on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $502.58.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $481.16 on Friday. The company’s fifty day moving average price is $435.51 and its 200 day moving average price is $462.74. Vertex Pharmaceuticals has a 1 year low of $377.85 and a 1 year high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mutual Advisors LLC boosted its holdings in shares of Vertex Pharmaceuticals by 0.6% in the 3rd quarter. Mutual Advisors LLC now owns 3,710 shares of the pharmaceutical company’s stock valued at $1,751,000 after buying an additional 21 shares in the last quarter. Daymark Wealth Partners LLC increased its holdings in shares of Vertex Pharmaceuticals by 2.8% in the 3rd quarter. Daymark Wealth Partners LLC now owns 804 shares of the pharmaceutical company’s stock valued at $374,000 after purchasing an additional 22 shares in the last quarter. Grove Bank & Trust grew its stake in Vertex Pharmaceuticals by 5.7% in the 3rd quarter. Grove Bank & Trust now owns 410 shares of the pharmaceutical company’s stock valued at $191,000 after acquiring an additional 22 shares during the last quarter. Outlook Wealth Advisors LLC grew its stake in Vertex Pharmaceuticals by 2.8% in the 3rd quarter. Outlook Wealth Advisors LLC now owns 892 shares of the pharmaceutical company’s stock valued at $415,000 after acquiring an additional 24 shares during the last quarter. Finally, Dunhill Financial LLC grew its stake in Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 24 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.